Lacey: (Background - CA teachers breast cancer study, went from paper to QR codes and SFDC, from 2 weeks to minutes) #AACR17
7:21am April 5th 2017 via Hootsuite
Lacey: Addressed pre-analytical var up-front. Logistics is the skillset they needed - so they used SFDC (!) and it worked very well #AACR17
7:19am April 5th 2017 via Hootsuite
Lacey: They hit their numbers. @jimlaceyjr at #AACR17 (a first time I'm seeing a Twitter address on a presentation footer!)
7:18am April 5th 2017 via Hootsuite
Lacey: Why collection in CA to biobank in Rockville MD? "Thermo had the scale". Collected 14K blood samples from Aug '13 to Aug '16. #AACR17
Lacey: When done right (and it's not hard to do) PHI is easier to do via cloud and mobile; much more secure than paper #AACR17
7:17am April 5th 2017 via Hootsuite
Lacey: "Mobile enables everything" - tracking samples collection through FedEx labels. Uses Fisher Scientific @thermofisher #AACR17
7:16am April 5th 2017 via Hootsuite
James Lacey (City of Hope CA) Improve your research with a new-technologies strategy #AACR17
7:15am April 5th 2017 via Hootsuite
MT @Duncande: NIH Director Francis Collins responds with stoicism to Trump's deep cuts to R&D https://t.co/L2xTtrdyNN
6:15pm April 4th 2017 via Hootsuite
Nesselbush: Proprietary lab and bioinformatics; applicable in early-stage cancer. #AACR17
4:21pm April 4th 2017 via Hootsuite
Nesselbush: Mismatch repair pathway assoc'd with PD-1 blockade resp Le NEJM '15 https://t.co/gIRzz3sSYG #AACR17
4:20pm April 4th 2017 via Hootsuite
Nesselbush:Ampl (>4x) 97.2% sens, >99% spec. MSI >2%, >99%/>99%. Muts to >0.5% #AACR17
4:17pm April 4th 2017 via Hootsuite
Nesselbush:PlasmaSELECT 64, used 'pan-cancer contrived samples', known alterations det by orthogonal methods #AACR17
4:16pm April 4th 2017 via Hootsuite
Nesselbush: 58 genes, 19 for ampl, 17 for rearr, 5 for MSI (BAT25, BAT26, NR21, NR24, MONO27) #AACR17
4:15pm April 4th 2017 via Hootsuite
Nesselbush: Early, localized, metastatic, refractory. Developed TEC-Seq, hyb-capture. Can do amplifications, rearr (PARE) MSI #AACR17
4:14pm April 4th 2017 via Hootsuite
Nesselbush: 10-25% of NSCLC insuff tissue; rebiopsy ma limit enrollment. Applications in ID resistance muts. #AACR17
4:13pm April 4th 2017 via Hootsuite
Monica Nesselbush (PGDx MD) Clinical validation of a cfDNA liquid biopsy approach for non-invasive molecular profiling #AACR17
4:10pm April 4th 2017 via Hootsuite
Q: Amt of blood for iChip? Karabacak: Blood is fixed to stop signaling; fresh can be used. 20 mL blood to a few hundred uL #AACR17
Q: Degree of loss of CTCs? Karabacak: Mass Cytometry uses 40% of the cells injected. Technology can be improved for selection #AACR17
4:09pm April 4th 2017 via Hootsuite
Karabacak: Unpublished ('do not post') data: data consistent to drug response. CTCs, primary tumor cells respond similarly #AACR17
4:07pm April 4th 2017 via Hootsuite
Karabacak: PC3 cells in vitro, apply BEZ235 (PI3K/mTOR inh), shows inhibition of growth. also signalling down regulation #AACR17
4:03pm April 4th 2017 via Hootsuite
Karabacak: Wanted to look at PI3K/mTOR signaling in mouse, using CyTOF from Fluidigm. #AACR17
4:01pm April 4th 2017 via Hootsuite
Karabacak: Reviews CTC platform iChip, 20M cells/sec, cell transit time 7sec '14 ref https://t.co/DCeHfO2noq #AACR17
Murat Karabacak (MA) Single cell signaling analysis reveals circulating tumor cell markers of drug suscept and tumor heterogeneity #AACR17
3:58pm April 4th 2017 via Hootsuite
Boonstra: 74% of pts with metastatic disease had KIT mutations. Imatinib resistance is assoc'd with secondary tumors #AACR17
3:42pm April 4th 2017 via Hootsuite
Peter Boonstra (GIST Consrt Netherlands) Dynamics of KIT exon 11 mutations in cfDNA of advanced gastrointestinal stromal tumors #AACR17
3:32pm April 4th 2017 via Hootsuite
Kuang: 36% of pts detected ESR1 in metastatic ER+ breast ca; AI treatment in adjuvant and metastatic settings, noted clonal section #AACR17
3:30pm April 4th 2017 via Hootsuite
Kuang: Cp of primary tissue vs cfDNA (n=45); 2 ESR1 mutations (out of 23) picked up in cfDNA not in tissue #AACR17
3:29pm April 4th 2017 via Hootsuite
Kuang: Also many more ESR1 in replapse metastatic vs de novo metastatic. ESR1 muts in liver/bone; not in lung #AACR17
3:25pm April 4th 2017 via Hootsuite
Kuang: Early stg disease not assoc'd w/ESR1; metastatic is assoc'd w/ESR1 mutations #AACR17
3:23pm April 4th 2017 via Hootsuite
Kuang: Also PIK3CA E545K and H1042R. n=155, ESR1 35 muts; PIK3CA: 42 muts 36% of ER+ mBrCa ESR1 mutated #AACR17
Kuang: Looking at Estrogen Receptor (ER) mutations and ESR1 E380Q, Y537S, also PIK3CA E542K emergence in ER+ via ddPCR in plasma #AACR17
3:21pm April 4th 2017 via Hootsuite
Yanan Kuang (Dana Farber MA) The emergence of ESR1 mutations is assoc'd with aromatase inh and fulvestrant therapy #AACR17
3:18pm April 4th 2017 via Hootsuite
Diehn: (Says a lot of interesting things that confirms prior data on AF in ctDNA, gene prevalence. ROC analysis, tumor burden too) #AACR17
11:20am April 4th 2017 via Hootsuite
Diehn: MRD in NSCLC could allow escalation of consolidation or adjuvant Rx. Prospective study 'do not post' early data #AACR17
11:17am April 4th 2017 via Hootsuite
Diehn: Looking at MRD - radiographically negative, no MRD for NSCLC. Useful in breast ca '15 ref https://t.co/TtBf5LoAbO #AACR17
11:15am April 4th 2017 via Hootsuite
Diehn: Adv NSCLC, looking at L858R, Exon 19 del, T790M: Sen 93%, Spec 100%. #AACR17
11:14am April 4th 2017 via Hootsuite
Diehn: Built models to suppress systematic error further - 'background polishing'. integrated digital error suppression (IDES) #AACR17
11:13am April 4th 2017 via Hootsuite
Diehn: Increasing LOD by increasing muts - cp 1 vs 8. Shows all base changes from 0 to 0.03% - systematic G>T, C>T, G>A, T>C #AA
11:12am April 4th 2017 via Hootsuite
Diehn: wanted to increase recovery, decrease error, more mutations '16 Nature Biotech https://t.co/ieiO0VyxvE #AACR17
11:11am April 4th 2017 via Hootsuite
Diehn: That's 2.5 per million. '14 ref https://t.co/MQDWcwRCQE Showed Stg IIB NSCLC pre-Tx and 5mos later from paper #AACR17
11:10am April 4th 2017 via Hootsuite
Diehn: Describes CAPP-Seq, 300genes, hyb capture-based, sens 0.002% generalized; 0.0025% personalized #AACR17
11:07am April 4th 2017 via Hootsuite
Diehn: After recurrence, systemic Tx response, resistance var already being done. #AACR17
11:06am April 4th 2017 via Hootsuite
Diehn: Non-invasive genotyping routinely done for a number of tumor types. Localized disease next, MRD, surveillance (repl imaging) #AACR17
Max Diehn (Stanford CA) Personalized cancer detection and monitoring via deep sequencing of circulating tumor DNA #AACR17
11:03am April 4th 2017 via Hootsuite
Q: Real-time pharmacodynamic modulation? Haber: Most 4w post-Tx. Still experimental stage. #AACR17
Q: Applied to urine CTCs? Haber: Haven't done, iChip is for 1 in a billion; urine is acellular. Other microfluidics also may apply #AACR17
11:02am April 4th 2017 via Hootsuite
Q: Culture artifact vs original CTC? Haber: 2-4 mo to culture, do repeat sampling. Same pt, same mut's. Need to validate back to pt #AACR17
11:01am April 4th 2017 via Hootsuite
Haber: Impt of high-prevalence disease: PPV: 10% prev -> 92% TPs. 0.1% prev -> 9% TPs. 0.01% -> 0.9% TPs #AACR17
10:58am April 4th 2017 via Hootsuite
Haber: And also distinguish between aging-associated molecular abnormalities. And high-risk population very impt. #AACR17
10:57am April 4th 2017 via Hootsuite
Haber: droplet PCR, sequence-based will help sens/spec. Need for tissue-of-origin, distinction from indolent proliferation #AACR17
10:56am April 4th 2017 via Hootsuite
